نتایج جستجو برای: 006
تعداد نتایج: 4625 فیلتر نتایج به سال:
Methods In an open-label, single-treatment arm trial, eight patients with Schnitzler’s syndrome received monthly injections with 150 mg canakinumab subcutaneously for 6 months, followed by a 3-month observation period. Primary outcome was complete or clinical remission at day 14. Secondary outcome measures included inflammatory markers, quality of life, time to relapse, safety and tolerability.
Case report 14 year old girl was admitted to our department with pain, low and moderate grade fever, delay to thrive and history of osteomyelitis. Her family history was unremarkable. The onset of disease was in the age of 10 months with small bone lesion in distal epiphysis of femur and intensive irritability. After 1 month of immobilization she had an intensive bone overgrowth with periostal ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید